Gossamer Bio

Gossamer Bio Revenue

The The revenue of Gossamer Bio (GOSS) as of Nov 20, 2026 is 48.47 M USD. In the previous year, The revenue was 114.70 M USD — a change of -57.74% (lower).

Revenue

48.47 MUSD

YoY

-57.74%

Last updated:

In 2025, Gossamer Bio's sales reached 48.47 M USD, a -57.74% difference from the 114.70 M USD sales recorded in the previous year.

The Gossamer Bio Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
Date
Revenue
Jan 1, 2023
0.00 USD
Jan 1, 2024
114.70 M USD
Jan 1, 2025
48.47 M USD
Jan 1, 2026 (e)
64.61 M USD
Jan 1, 2027 (e)
17.94 M USD
Jan 1, 2028 (e)
82.78 M USD
Jan 1, 2029 (e)
165.99 M USD
Jan 1, 2030 (e)
272.91 M USD
The Gossamer Bio Revenue history
YEARRevenueYoY
est272.91 MUSD+64.41%
est165.99 MUSD+100.53%
est82.78 MUSD+361.33%
est17.94 MUSD-72.23%
est64.61 MUSD+33.29%
48.47 MUSD-57.74%
114.70 MUSD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Gossamer Bio Revenue

Gossamer Bio Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
0.00 USD
-183.76 M USD
-179.82 M USD
Jan 1, 2024
114.70 M USD
-59.92 M USD
-56.53 M USD
Jan 1, 2025
48.47 M USD
-161.44 M USD
-170.37 M USD
Jan 1, 2026 (e)
64.61 M USD
-52.30 M USD
-53.56 M USD
Jan 1, 2027 (e)
17.94 M USD
-11.99 M USD
-17.99 M USD
Jan 1, 2028 (e)
82.78 M USD
-554,433.00 USD
-11.11 M USD
Jan 1, 2029 (e)
165.99 M USD
15.59 M USD
2.83 M USD
Jan 1, 2030 (e)
272.91 M USD
37.48 M USD
20.13 M USD

Gossamer Bio Margins

Gossamer Bio stock margins

The Gossamer Bio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Gossamer Bio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Gossamer Bio.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
97.93 %
- %
- %
Jan 1, 2024
100.00 %
-52.24 %
-49.28 %
Jan 1, 2025
97.93 %
-333.06 %
-351.49 %
Jan 1, 2026 (e)
97.93 %
-80.94 %
-82.91 %
Jan 1, 2027 (e)
97.93 %
-66.81 %
-100.25 %
Jan 1, 2028 (e)
97.93 %
-0.67 %
-13.42 %
Jan 1, 2029 (e)
97.93 %
9.39 %
1.71 %
Jan 1, 2030 (e)
97.93 %
13.73 %
7.37 %

Gossamer Bio Stock analysis

What does Gossamer Bio do? The company Gossamer Bio Inc. was founded in 2015 by Faheem Hasnain and Sheila Gujrathi. The founders had previously worked at various biotechnology companies and now wanted to start their own company to develop innovative products in the field of immunology. Gossamer Bio is headquartered in San Diego, California and currently employs around 200 people. The company specializes in researching and developing therapeutics for a wide range of diseases, including respiratory diseases, cancer, immunological disorders, and infections. Gossamer Bio's business model is based on identifying promising new drug candidates and subsequently developing therapeutics that have the potential to improve patients' lives. Key pillars of the business model include partnerships with established companies and investors, as well as the rapid and efficient conduct of clinical trials. Gossamer Bio's portfolio includes various pipeline programs in different stages of development. An important focus is on the development of new drugs for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). A promising drug candidate in this area is GB001, an inhalation medication that aims to reduce inflammation in the airways. Another important program of Gossamer Bio is the development of therapeutics for the treatment of cancer. The company focuses on the development of drugs that target the body's immune system to specifically fight tumor cells. A promising drug candidate in this area is GB1275, an antibody that specifically targets a protein overexpressed by some types of cancer. In addition to these two focus areas, Gossamer Bio also has programs in the development of therapeutics for the treatment of immunological disorders such as inflammatory bowel disease and rheumatoid arthritis, as well as for the treatment of infections such as COVID-19. Overall, Gossamer Bio has a wide range of promising drug candidates that have the potential to revolutionize the field of immunology and disease management. The company is well positioned to make significant progress in the development of new therapeutics in the coming years and improve the lives of millions of patients worldwide. Gossamer Bio is one of the most popular companies on Eulerpool.

Revenue Details

Understanding Gossamer Bio's Sales Figures

The sales figures of Gossamer Bio originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Gossamer Bio’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Gossamer Bio's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Gossamer Bio’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Gossamer Bio stock

The revenue of Gossamer Bio is 48.47 M USD in 2025.

The revenue of Gossamer Bio changed from 114.70 M USD to 48.47 M USD, representing a -57.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The revenue Gossamer Bio since 2006 – with annual values, charts, and detailed analysis.

Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).

The revenue's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's Gossamer Bio historically and in real time.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Gossamer Bio

All Key Metrics — Gossamer Bio